WNK1抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: TM4 cells, Primary antibody: P05524(WNK1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05524(WNK1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P05524(WNK1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

WNK1 (With No Lysine [K] 1) is a serine/threonine kinase critical for regulating ion transport and cellular electrolyte balance. It is named for its atypical kinase domain lacking a conserved lysine residue typically required for ATP binding. WNK1 plays a key role in maintaining blood pressure and renal function by modulating sodium, potassium, and chloride transporters, particularly the Na⁺-Cl⁻ cotransporter (NCC) and renal outer medullary potassium channel (ROMK). Dysregulation of WNK1 activity is linked to hypertension and familial hyperkalemic hypertension (FHHt), also known as Gordon syndrome, caused by mutations in WNK1 or its interacting proteins.

WNK1 antibodies are essential tools for studying its expression, phosphorylation, and interactions in physiological and pathological contexts. These antibodies are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect WNK1 isoforms (e.g., L-WNK1 and KS-WNK1) in tissues such as the kidney, brain, and cardiovascular system. Researchers also employ WNK1 antibodies to investigate its role in signaling pathways, including the RAS-MAPK cascade and cellular stress responses.

Challenges in WNK1 antibody development include specificity due to isoform diversity and post-translational modifications. Commercial antibodies are validated for cross-reactivity across species (human, mouse, rat) and applications. Understanding WNK1’s regulatory mechanisms via antibodies aids in exploring therapeutic targets for hypertension, kidney disorders, and cancers where WNK1 is aberrantly expressed.